



KEY HIGHLIGHTS

1. RESULTS OVERVIEW:

- Styrenix Q1FY25 consolidated revenues came in at ₹699 Cr, up 28.49% YoY and up 16.69% QoQ.
- Op Profit for Q1FY25 stood at ₹90 Cr, up 76.47% YoY and up 25% QoQ.
- Op margins for Q1FY25 came at 12.88%, +350 bps YoY and +86 bps QoQ.
- PAT for Q1FY25 stood at ₹61 Cr, up 90.63% YoY and up 24.49% QoQ.

2. MANAGEMENT COMMENTARY:

- Capacity addition plans of 1,51,000 TPA to 3,60,000 TPA by FY28 may be done earlier also. Engineering studies are going on currently.
- Realizations have improved due to product mix and not by price increase.Capacity utilization is near 100%.
- Company is trying to lower fuel and power cost may aid in margins in coming quarters.

3. CONCALL SUMMARY

- Debottlenecking projects ongoing to increase capacity.
- Capacity expected to reach 100-105,000 tonnes of ABS this year.
- Launched products under brand names STYROLOY and ASALAC.
- STYROLOY includes blends like polycarbonate ABS, nylon ABS, ABS PMMA, HIPS, PPO.
- Undertaking projects to reduce power and fuel costs.
- No major impact of Red sea issue on the imports of ABS in the country.
- Targeting 60-70 cr Capex in FY25.

4. Recent DEVELOPMENTS:

- Styrenix Performance Materials FZE, a wholly owned subsidiary of the company has been incorporated on September 10, 2024.
- The wholly own subsidiary is incorporated at free trade zone at UAE with object of General Trading.
- Entire promoter pledge has been cleared by the promoters of the company.

5. VALUATION AND OUTLOOK:

- Styrenix is the market leader in ABS manufacturing in India and one of the largest producers of Polystyrene (PS). ABS and PS find their application in automobiles, home appliances, stationary, etc.
- Styrenix is a good play on the increasing discretionary spending and manufacturing boom that India is expected to witness.
- A large proportion of the ABS demand in India is met by imports. Currently there are only two players manufacturing ABS in India. The other company is Bhansali Engineering. Supreme Petrochem has also announced capacity in ABS. However, we still believe that there will be sufficient demand in India to absorb these capacity addition as the industry is expected to grow at high single digit to low double digit and import substitution will aid well to the demand growth.
- We are projecting a 20%/27%/26% Revenue/EBITDA/PAT CAGR for FY24-28 period. The stock is trading at 15.5 times its FY26E EPS, which we believe is quite attractive.
- We value the company at 18.5 times its FY26E EPS of 159, to arrive at a target price of 2,942 implying an upside of 19.11%.

RECOMMENDATION - BUY CMP – 2470 TARGET – 2942 (19%)

Industry	Chemicals
NSE CODE	STYRENIX
BSE CODE	506222
Market Cap (₹ Cr)	4418.21
Shares Outstanding (in	
Cr)	1.76
52 wk High/Low (₹)	2880 / 1030
P/E	21.88
P/BV	5.64
Face Value (₹)	10.00
Book Value (₹)	445.78
EPS (FY24) (₹)	98.45
Dividend Yield (%)	6.83
Debt / Equity	0.01

SHAREHOLDING PATTERN

	Dec 23	Mar 24	June 24
Promoters	62.73	62.73	46.24
MF/ DII	5.01	4.99	10.58
FII/FPI	2.53	2.09	4.96
Retail & Others	29.72	30.18	38.21
Promoter			
Pledging	100.00	100.00	92.41

FINANCIAL SNAPSHOT (₹ Cr)

2024A	2025E	2026E
2,222	2,840	3,139
-6.3%	27.8%	10.5%
264	383	440
11.9%	13.5%	14.0%
173	246	280
98	140	159
-5.5%	42.2%	13.8%
24.09	33.1	34.1
32.5	35.2	34.2
25.20	17.64	15.53
	2,222 -6.3% 264 11.9% 173 98 -5.5% 24.09 32.5	2,222 2,840 -6.3% 27.8% 264 383 11.9% 13.5% 173 246 98 140 -5.5% 42.2% 24.09 33.1 32.5 35.2


Historical & Indust	trial Val Ratios
Historical P/E	18.5
Industry P/E	20.5
Historical P/B	2.2
Industry P/B	3.0






Volume Data (Q1 FY25)

Sales Volume (MT) for the Quarter



Sales Volumes (MT) for the Year



QUARTERLY PERFORMANCE (CONSOLIDATED)

(₹ Cr)

Y/E March	F	Y23		FY24	k i i		FY25		FY24	FY25E*
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2FY25E*	F124	FIZJE
Net sales	557	615	544	595	485	599	699	710	2,222	2,840
YoY change (%)	8.9%	-1.4%	-16.3%	8.2%	-13.0%	-2.7%	28.5%	19.3%	-6.33%	28%
Total Expenditures	508	549	493	512	427	527	609	614	1,958	2,457
EBITDA	49	66	51	83	58	72	90	96	264	383
Margins (%)	9%	11%	9%	14%	12%	12%	13%	13.5%	12%	13.5%
Other income	2	3	2	3	2	2	2	2	9	7
Interest	1	1	1	1	1	1	1	1	4	10
Depriciation	9	10	9	9	9	9	9	10	37	48
PBT	40	58	43	76	50	64	82	87	233	332
Rate (%)	25%	27%	25%	26%	30%	23%	26%	26%	26%	26%
Adjusted PAT	30	42	32	56	35	49	61	64	173	246
EPS in Rs	17.17	24.13	18.45	32.08	19.87	28.07	34.66	36.58	98.47	139.7

Source: Company, Hem Securities Research.






INDUSTRY OVERVIEW

- ABS and polystyrene are integral materials in industries like automotive, electronics, construction, and consumer products, valued for their strength, durability, and adaptability.
- ABS demand is on the rise due to its use in lightweight and durable products such as automotive components and electronics, while polystyrene continues to be a key material in packaging and insulation applications.
- The Indian market is seeing a surge in demand for ABS, driven by growth in sectors such as automotive and electronics, along with expanding consumer goods industries.
- Polystyrene demand in India is being fueled by the expanding packaging industry, especially in food, beverage, and retail segments.
- India relies significantly on imports for ABS and polystyrene raw materials, making it susceptible to global price fluctuations and supply challenges.
- In India there are only two manufacturers of ABS (Styrenix Performance Materials and Bhansali Engineering Polymers). Both of them are expanding their capacities significantly. Supreme Petrochem has also announced capacity in ABS.

KEY PLAYERS in ABS Industry



PEER PERFORMANCE

Particulars	Styrenix	Supreme	Bhansali
	Performance	Petrochem	Engineering
Market Cap	4381.2	16292.9	3887.1
Net Sales	2377.1	5601.7	1267.3
EBITDA	264.3	473.2	212.0
РАТ	173.2	346.5	179.7
EPS(₹)	114.8	21.2	7.3
EBITDA MARGIN %	12.7%	9.6%	17.1%
PAT MARGIN %	7.8%	6.2%	14.7%
ROCE %	31.4%	22.5%	24.4%
ROE %	24.0%	16.8%	18.1%
P/E TTM	21.7	40.8	21.3
P/B TTM	6.1	8.1	4.2
EV/EBITDA	14.0	26.0	14.3
Dividend Yield %	4.0%	1.0%	2.6%
M Cap/ Sales TTM	1.8	2.9	3.1


Source: Company, Hem Securities Research.

(₹ Cr)





STORY IN CHARTS







INVESTMENT RATIONALE:

- Company manufactures ABS (a type of plastic) used in Automobile, Electronic appliances, Stationary, EVs, Medical equipment, etc. Hence it is a good proxy of increasing discretionary spend in the country.
- Styrenix is the market leader in ABS in India. There are only two companies that manufactures this product, the other is Bhansali Engineering. Styrenix has 30% market share.
- The industry is expected to grow at high single digit to low double digit. Approximately half of the demand of ABS in India is met from imports.
- Styrenix is adding significant capacity for ABS as well as Polystyrene. It is looking to substitute imports and gain further market share.
- Company's well established brand name and long standing client relationships will aid in business growth.
- ABS and Polystyrene prices are at multi year low. Given the interest rate cut cycles have started globally and China announcing stimulus packages to revive its economy, we believe commodity pricing cycle may make a comeback in coming quarters.
- We are projecting a 20%/27%/26% Revenue/EBITDA/PAT CAGR for FY24-28 period. The stock is trading at 15.5 times its FY26E EPS, which we believe is quite attractive.

RISK / NEGATIVE FACTORS:

- Further drop in commodity prices.
- Delay in capacity ramp up.
- Environmental risks related to uses of plastic.

COMPANY RECAP

- Styrenix Performance Materials Limited (formerly known as INEOS Styrolution India Limited) is the number one producer of Absolac (ABS) and Absolan (SAN) in India.
- ABS is a plastic resin produced from acrylonitrile, butadiene and styrene, used for manufacturing home appliances, automobiles, consumer durables and machinery.
- Absolan (SAN) is a polymerized plastic resin produced from styrene and acrylonitrile, and mainly used for products such as lighting, stationery, novelties, refrigerators and cosmetic packing.
- With 45 years of pioneering experience, Styrenix Performance Materials Limited has been the most preferred supplier to its customers.
- It has 30% Market share in ABS and 20% in Polystyrene.
- Company is planning to increase ABS capacity from 85,000 TPA to 210,000 TPA by FY28. Also, PS capacity to increase from 66,000 TPA to 150,000 TPA by FY27.





ANNUAL PERFORMANCE

Financials & Valuations							
Income Statement							(₹ Cr)
Y/E March	2020	2021	2022	2023	2024	2025E	2026E
Revenue from operations	1579	1631	2179	2372	2222	2840	3139
Growth YoY (%)	-24.5%	3.3%	33.6%	8.9%	-6.3%	27.8%	10.5%
Total Expenditure	1514	1218	1704	2096	1958	2457	2699
(%) of sales	95.9%	74.7%	78.2%	88.4%	88.1%	86.5%	86.0%
EBITDA	65	414	475	276	264	383	440
EBITDA Growth (%)	622.2%	536.9%	14.7%	-41.9%	-4.3%	45.1%	14.9%
EBITDA Margin (%)	4.1%	25.4%	21.8%	11.6%	11.9%	13.5%	14.0%
Depreciation	32	36	38	38	37	48	52
EBIT	33	378	437	238	227	335	388
EBIT Growth (%)	NA	1045.5%	15.6%	-45.5%	-4.6%	47.6%	15.8%
Net Interest Expenses	16	15	8	6	4	10	15
Other Income	-31	13	14	15	9	7	6
Earnings before Taxes	-14	376	443	247	232	332	379
EBT Margin (%)	-0.9%	23.1%	20.3%	10.4%	10.4%	11.7%	12.1%
Tax-Total	-4	96	120	64	59	86	99
Rate of tax (%)	29%	26%	27%	26%	25%	26%	26%
Net Profit	-10	280	323	183	173	246	280
PAT Growth (%)	NA	NA	15.4%	-43.3%	-5.5%	42.2%	13.8%
PAT Margin (%)	-0.6%	17.2%	14.8%	7.7%	7.8%	8.7%	8.9%
Minority Interest	0	0	0	0	0	0	0
Adjusted PAT	-10	280	323	183	173	246	280
EPS	-6	159	184	104	98	140	159
EPS Growth (%)	NA	NA	15.4%	-43.3%	-5.5%	42.2%	13.8%

Balance Sheet

Dalance Sheet					
Y/E March	2020	2021	2022	2023	2024
Equity Capital	18	18	18	18	18
Reserves	592	871	839	697	705
Borrowings	224	98	52	35	27
Other Liabilities	222	326	323	513	288
Total Liabilities & Equity	1,055	1,313	1,232	1,263	1,038
Fixed Assets	365	369	343	309	295
CWIP	56	30	7	12	28
Investments	0	1	1	1	58
Other Assets	634	914	881	940	657
Total Assets	1,055	1,313	1,232	1,263	1,038

Source: Company, Hem Securities Research.





Ratios					
Y/E March (Basic (INR)	2020	2021	2022	2023	2024
Profitability and return ratios					
Net profit margin (%)	-0.6	17.09	14.75	7.67	7.68
EBITDA margin (%)	4.53	26.02	22.34	12.18	12.13
EBIT margin (%)	0.15	23.82	20.61	10.59	10.5
ROE (%)	-1.55	37.41	36.96	23.3	24.09
ROCE (%)	0.29	45.32	49.86	31.77	32.5
Working Capital & liquidity ratios					
Inventory (Days)	67.18	62.14	52.68	52.52	49.71
Receivables (Days)	46.93	53.22	51.12	47.8	49.82
Current Ratio (x)	1.79	2.96	2.96	1.92	2.71
Valuations Ratios					
EV/sales (x)	0.68	0.89	0.71	0.43	1.11
EV/EBITDA (x)	14.92	3.41	3.16	3.51	9.05
P/E (x)	0.00	5.87	5.31	6.86	14.57
P/BV (x)	1.48	1.85	2.00	1.76	3.49
Dividend Yield (%)	0.00	1.07	30.48	14.56	6.83
Leverage Ratio					
Debt/Equity (x)	0.28	0.06	0.01	0.01	0.01

Cash Flow Statement					
Y/E March	2020	2021	2022	2023	2024
CF from Operating activities (A)	166	385	356	270	216
CF from Investing Activities (B)	-84	-112	83	-136	-88
CF from Financing Activities (C)	-124	-137	-412	-198	-177
Net Cash Flow	-42	136	27	-63	-48
Add: Opening Bal.	46	3	242	179	245
Closing Balance	3	242	179	245	57

Source: Company, Hem Securities Research.





RATING CRITERIA

INVESTMENT RATING	EXPECTED RETURN	
BUY	>=15%	
ACCUMULATE	5% to 15%	
HOLD	0 to 5%	
REDUCE	-5% to 0	
SELL	<-5%	

RECOMMENDATI	ON SUMMAR	RY
DATE	RATING	TARGET
25 September 2024	Buy	2,942

DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.





We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

ANALYST CERTIFICATION/ DISCLOSURE OF INTEREST

Name of the Research Analyst: Akshat Vijay

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

SN	Particulars	Yes/No
1.	Research Analyst or his/her relative's or HSL's financial interest in the subject company(ies)	No
2.	Research Analyst or his/her relative or HSL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report	No
3.	Research Analyst or his/her relative or HSL has any other material conflict of interest at the time of publication of the Research Report	No
4.	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5.	HSL has received any compensation from the subject company in the past twelve months	No
6.	HSL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7.	HSL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8.	HSL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9.	HSL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10.	Research Analyst or HSL has been engaged in market making activity for the subject company(ies)	No

Since HSL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months. Associates of HSL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

There were no instances of non-compliance by HSL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.